These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26484094)

  • 1. Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
    Nevedomskaya E; Wessels L; Zwart W
    Genom Data; 2014 Dec; 2():195-8. PubMed ID: 26484094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
    Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
    Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology.
    Amatori S; Persico G; Paolicelli C; Hillje R; Sahnane N; Corini F; Furlan D; Luzi L; Minucci S; Giorgio M; Pelicci PG; Fanelli M
    Clin Epigenetics; 2018 Nov; 10(1):143. PubMed ID: 30446010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.
    Nevedomskaya E; Stelloo S; van der Poel HG; de Jong J; Wessels LF; Bergman AM; Zwart W
    Genom Data; 2016 Mar; 7():124-6. PubMed ID: 26981385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of ChIP-seq data uncovers dynamic and sustained H3K4me3 and H3K27me3 modulation in cancer cells under hypoxia.
    Adriaens ME; Prickaerts P; Chan-Seng-Yue M; van den Beucken T; Dahlmans VEH; Eijssen LM; Beck T; Wouters BG; Voncken JW; Evelo CTA
    Epigenetics Chromatin; 2016; 9():48. PubMed ID: 27822313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
    Harvell DM; Richer JK; Singh M; Spoelstra N; Finlayson C; Borges VF; Elias AD; Horwitz KB
    Breast Cancer Res Treat; 2008 Dec; 112(3):489-501. PubMed ID: 18338247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium falciparum epigenome: A distinct dynamic epigenetic regulation of gene expression.
    Rawat M; Bhosale MA; Karmodiya K
    Genom Data; 2016 Mar; 7():79-81. PubMed ID: 26981368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What do we know about the mechanisms of aromatase inhibitor resistance?
    Chen S; Masri S; Wang X; Phung S; Yuan YC; Wu X
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):232-40. PubMed ID: 17055257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
    Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
    Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide epigenetic cross-talk between DNA methylation and H3K27me3 in zebrafish embryos.
    de la Calle Mustienes E; Gómez-Skarmeta JL; Bogdanović O
    Genom Data; 2015 Dec; 6():7-9. PubMed ID: 26697317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
    Manna PR; Molehin D; Ahmed AU
    Prog Mol Biol Transl Sci; 2016; 144():487-537. PubMed ID: 27865465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.